Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 46 of 58, showing 10 Applications out of 576 total, starting on record 451, ending on 460

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

451.

ECCT/24/03/03   DoxyDOT Study
    Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI CMR RCTP
 
31-05-2024 View

452.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
19-06-2024 View

453.

ECCT/24/03/05   221163 PALISADE
    Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition   
Principal Investigator(s)
1. Grace Mboya
Site(s) in Kenya
KEMRI Kisumu Clinical Research Site
 
10-05-2024 View

454.

ECCT/24/03/06   PHOENIx MDR-TB)
    Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)   
Principal Investigator(s)
1. Dr Lucy Chepkurui Koech KOECH
Site(s) in Kenya
1. Kenya medical Research Institute/ Walter Reed Project (Kericho county)
2. Moi university clinic research Centre (Uasin Gishu county)
 
21-05-2024 View

455.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
25-04-2024 View

456.

ECCT/24/04/01   B/F/TAF to DTG/3TC Switch Stud
    Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kenyatta National Hospital (Nairobi City county)
 
02-06-2024 View

457.

ECCT/24/04/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Fredrick Kipyego Sawe
Site(s) in Kenya
1. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
 
03-07-2024 View

458.

ECCT/24/04/03   SMAART-MAP trial
    Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial   
Principal Investigator(s)
1. Prof Kathryn Maitland Maitland
Site(s) in Kenya
Kilifi County Hospital
 
29-08-2024 View

459.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
19-09-2024 View

460.

ECCT/24/04/05   Phase III Vitiligo Study
                                                                             A Double-Arm, Open Label, Phase III Study to Compare the                                           Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-                                                                                    UVB Light Alone in the Treatment of Vitiligo   
Principal Investigator(s)
1. Dr. Hannah Wanyika Wanyika
Site(s) in Kenya
Kenyatta National Hospital -
 
30-08-2024 View